BMRN Earnings & Financial Statements
BioMarin Pharmaceutical Inc.
$57.30
+$2.16(+3.92%)
48
Overall
65
Value
27
Tech
52
Quality
Market Cap
$10.67B
Volume
216.80K
52W Range
$49.26 - $70.98
Target Price
$90.77
BMRN earnings and financial statements: BioMarin Pharmaceutical Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BMRN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Cost of revenue | $717.44M | $580.24M | $532.06M | $483.67M | $470.51M |
| Operating income | $409.48M | $484.21M | $185.77M | $149.56M | -$82.34M |
| EBITDA | $575.56M | $654.21M | $314.47M | $271.04M | $47.43M |
| Net income | $348.90M | $426.86M | $167.65M | $141.56M | -$64.08M |
| EPS (diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B |
| Total liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B |
| Shareholders’ equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B |
| Cash and equivalents | $1.31B | $942.84M | $755.13M | $724.53M | $587.28M |
| Long-term debt | $597.18M | $595.14M | $593.10M | $1.08B | $1.08B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $827.99M | $572.84M | $159.26M | $175.90M | $304.54M |
| Capital expenditure | -$110.97M | -$97.42M | -$107.61M | -$131.54M | -$119.22M |
| Free cash flow | $717.02M | $475.42M | $51.65M | $44.36M | $185.31M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BMRN | $57.30 | +3.9% | 216.80K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get BioMarin Pharmaceutical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW